Abstract Library

#4471 Acromegaly and small intestinal neuroendocrine tumours: Association or coincidence?

Introduction: Neuroendocrine tumours of the small intestine (SI-NETs), although rare, are the most prevalent primary neoplasms of this organ. Acromegaly is characterised by excessive secretion of growth hormone (GH), typically due to a pituitary adenoma, but in rare cases, it can result from ectopic secretion of GH-releasing hormone (GHRH) by non-pituitary tumours, particularly NETs of the lung or pancreas.

Conference:

Presenting Author: G. Martins R

Authors: Martins Fernandes A, Silva L, Serranito M, Elvas A, Santos J,

Keywords: neuroendocrine tumour, small intestinal neuroendocrine tumour, acromegaly,

#4370 Role of 68GA-DOTATOC pet/ct in therapeutic decision-making for well-differentiated neuroendocrine tumours

Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.

Conference:

Presenting Author: Cruz-Diaz W

Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,

Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,

#4180 Non-functional alpha-cell hyperplasia with glucagonoma: A case report

Introduction: Alpha-cell hyperplasia(ACH) is a rare pancreatic endocrine condition. Clinically, 3 types have been described: functional ACH (nonglucagonoma hyperglucagonemic glucagonoma syndrome), reactive ACH (secondary to defective glucagon signalling) and non-functional ACH. Few cases of ACH and non-functional pancreatic neuroendocrine tumors (pNET) have been reported and its aetiology remains poorly understood.

Conference:

Presenting Author: Santos A

Authors: Cidade Rodrigues C, Santos A, Calheiros R, Santos S, Matos C,

Keywords: alpha-cell hyperplasia, diabetes, glucagon, pancreas, neuroendocrine tumor,

#4162 Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is recommended in unresectable and metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs), however, recommendations for functioning NENs (F-NENs) are not well established. Besides PRRT impact in OS and PFS, real-life benefit in clinical control is also a relevant outcome, especially in F-NENs.

Conference:

Presenting Author: Santos A

Authors: Lopes-Pinto M, Silva D, Ribeiro S, Oliveira J, Ferreira G,

Keywords: neuroendocrine neoplasm, functioning neuroendocrine neoplasm, carcinoid syndrome, PRRT,

#3920 Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary

Introduction: The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel approaches in the management of neuroendocrine tumors (NETs).

Conference:

Presenting Author: Chianpian C

Authors: Chianpian C, Bautista-Peñalosa P, Santos C, Bandong I,

Keywords: peptide receptor radionuclide therapy, metastatic pancreatic neuroendocrine tumor, Ga-68 DOTATATE, Lu-177 DOTATATE, Philippines,